Just another reason to query the Daybue revenue downgrade:
Joel Beatty | Robert W. Baird Stock Analyst - TipRanks.comJoel Beatty is a 4.69-star Wall Street Analyst at Robert W. Baird. Joel Beatty's focuses on the Healthcare sector and covers 72 stocks with a 48.99% success rate
Joel Beatty has given his Buy rating due to a combination of factors surrounding ACADIA Pharmaceuticals’ financial performance and market opportunities. Despite a decrease in revenue guidance for Daybue, Beatty acknowledges the potential for this drug to be a longer-term growth opportunity. He cites the steady increase in Daybue’s revenue over the previous quarters and the management’s report that over 30% of diagnosed Rett syndrome patients in the United States had started treatment by the end of the second quarter. Additionally, the rate of discontinuations decreased, and patient growth continued, suggesting a positive trend for future sales.
Kens
- Forums
- ASX - By Stock
- NEU
- Share Price
Share Price, page-11133
-
- There are more pages in this discussion • 25 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add NEU (ASX) to my watchlist
|
|||||
Last
$15.82 |
Change
-0.410(2.53%) |
Mkt cap ! $2.034B |
Open | High | Low | Value | Volume |
$16.33 | $16.37 | $15.82 | $6.457M | 403.5K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
6 | 221 | $15.81 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$15.83 | 189 | 12 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 172 | 15.870 |
6 | 414 | 15.860 |
6 | 605 | 15.850 |
5 | 572 | 15.840 |
2 | 217 | 15.830 |
Price($) | Vol. | No. |
---|---|---|
15.880 | 311 | 11 |
15.890 | 556 | 7 |
15.900 | 400 | 7 |
15.910 | 312 | 4 |
15.920 | 552 | 5 |
Last trade - 14.06pm 13/08/2024 (20 minute delay) ? |
Featured News
NEU (ASX) Chart |
The Watchlist
ACW
ACTINOGEN MEDICAL LIMITED
Steven Gourlay, Managing Director and CEO
Steven Gourlay
Managing Director and CEO
SPONSORED BY The Market Online